Prima BioMed Ltd (PBMD) : The consensus price target for Prima BioMed Ltd (PBMD) is $5 for the short term with a standard deviation of $1.41. The most optimist securities analyst among the 4 who monitor the stock believes that the stock can reach $6, however, the pessimist price target for the company is $3.
Prima BioMed Ltd (PBMD) : The consensus on Prima BioMed Ltd (PBMD) based on 4 analyst recommendation on the company stock is 1, which is interpreted as a Strong Buy recommendation. Zacks Investment Research has issued a rank of 3 which endorses a Hold on the stock. However, 4 brokers have a differing view as they consider the stock to be a Strong Buy at current levels.
Prima BioMed Ltd (NASDAQ:PBMD): The stock opened at $0.87 on Thursday but the bulls could not build on the opening and the stock topped out at $0.87 for the day. The stock traded down to $0.85 during the day, due to lack of any buying support eventually closed down at $0.85 with a loss of -1.72% for the day. The stock had closed at $0.87 on the previous day. The total traded volume was 69,945 shares.
Prima BioMed Limited is an Australia-based biotechnology company. The Company is engaged in research, development and commercialization of licensed medical biotechnology. The Company focuses on cancer immunotherapy research. The Companys main pipeline of products is based on the LAG-3 immune control mechanism, which plays a role in the regulation of the T cell immune response. The Companys product is a T cell immunostimulatory factor (APC activator), IMP321, for cancer chemoimmunotherapy, which has completed Phase II trials. In addition, it has developed infrastructure for a cell-based therapy manufacturing platform and taken CVac, an autologous dendritic cell-based product through Phase II clinical trials for ovarian cancer patients in remission. The Companys other products include IMP731 for autoimmune disease, and IMP701 for cancer and chronic infectious disease.